November 24, 2025
2 min read
GLP-1 Pill Fails to Slow Alzheimer’s Progression in Clinical Trial
Top-line results from two large clinical trials by Novo Nordisk, the company behind Ozempic and Wegovy, found oral semaglutide failed to slow down Alzheimer’s progression
Brain CT scans of Alzheimer’s disease.
The pill version of Novo Nordisk’s blockbuster weight-loss medication, semaglutide, failed to slow down Alzheimer’s progression in an initial analysis of two clinical phase 3 trials. The company behind the weekly injectable diabetes medication Ozempic and weight-loss drug Wegovy, which are also known as GLP-1 drugs, announced the top-line results today.
Endocrinologist Daniel Drucker says that the trials were well-done but the results are “a setback for the field.” Novo Nordisk confirmed in a statement to Scientific American that the company is ending its semaglutide trials on Alzheimer’s, including tests involving the injectable version of the drug.
“GLP-1 [drugs] have given us so many wonderful results, but tackling these very challenging brain disorders has been disappointing,” says Drucker, who has consulted for Novo Nordisk in the past but does not currently. “No one expected that it was going to shut down the progression of Alzheimer’s disease, but there was a hope that we would see some benefit, and we didn’t.”
On supporting science journalism
If you’re enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.
Animal models and reviews of real-world data have previously suggested that GLP-1 drugs might reduce the risk or slow development of Alzheimer’s. The reason why remains elusive, although researchers including Drucker suggest that these drugs might reduce inflammation associated with certain neurological conditions.
“GLP-1 does reduce inflammation in many parts of the body, and inflammation does drive part of the pathology of Alzheimer’s,” he says.
Novo Nordisk’s trials, called evoke and evoke+, involved 3,808 people aged 55 to 85 who had early-stage Alzheimer’s, classified as having mild cognitive impairment as a result of the disease. During most of the 156-week trial, the researchers gave half the participants 14 milligrams of oral semaglutide once a day, while the other half received a placebo.
Participants who took the drug did show some improvements in Alzheimer’s biomarkers, but treatment didn’t delay disease progression, according to the company.
Drucker says there are many potential explanations why oral semaglutide didn’t work as hoped. The fatty-acid structure surrounding semaglutide might have prevented it from being able to penetrate certain brain regions, such as the hippocampus, which controls memory and cognitive function. Past studies evaluating the connection between GLP-1 treatment and Alzheimer’s risk or development have mostly drawn from data on the injectables, raising questions on whether changing how people take the drug or the dosage could elicit a different outcome, Drucker says, though he adds that giving higher doses to some older adults may also come with additional risks.
“These are not wonder drugs that will fix everything that is wrong with us, and that’s why we have to do the clinical trials, and we need rigorous evidence,” Drucker says, adding that Novo Nordisk deserves credit for doing the trials despite the low odds of success.
Novo Nordisk plans to present the findings at the Clinical Trials in Alzheimer’s Disease (CTAD) conference next week and the full datasets at the AD/PD Alzheimer’s and Parkinson’s Diseases Conference in March 2026.
“We will continue to analyze the data and may not have the answer to the ‘why’ next week when we share the results at CTAD,” a Novo Nordisk spokesperson told Scientific American.
It’s Time to Stand Up for Science
If you enjoyed this article, I’d like to ask for your support. Scientific American has served as an advocate for science and industry for 180 years, and right now may be the most critical moment in that two-century history.
I’ve been a Scientific American subscriber since I was 12 years old, and it helped shape the way I look at the world. SciAm always educates and delights me, and inspires a sense of awe for our vast, beautiful universe. I hope it does that for you, too.
If you subscribe to Scientific American, you help ensure that our coverage is centered on meaningful research and discovery; that we have the resources to report on the decisions that threaten labs across the U.S.; and that we support both budding and working scientists at a time when the value of science itself too often goes unrecognized.
In return, you get essential news, captivating podcasts, brilliant infographics, can’t-miss newsletters, must-watch videos, challenging games, and the science world’s best writing and reporting. You can even gift someone a subscription.
There has never been a more important time for us to stand up and show why science matters. I hope you’ll support us in that mission.
